ABCL Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
4.0M
-51.3%
8.3M
-81.5%
44.9M
+400.9%
9.0M
-47.6%
17.1M
Cost of Revenue
0
0
0
0
0
Gross Profit
4.0M
-51.3%
8.3M
-81.5%
44.9M
+400.9%
9.0M
-47.6%
17.1M
Operating Expenses
66.8M
+1.5%
65.8M
-10.4%
73.4M
-13.8%
85.2M
+27.8%
66.7M
R&D
46.0M
-1.4%
46.7M
-6.8%
50.1M
-9.0%
55.0M
+40.3%
39.2M
SG&A
13.8M
+12.3%
12.3M
-28.4%
17.2M
-31.0%
25.0M
+13.5%
22.0M
Operating Income
-62777000
-9.1%
-57519000
-101.2%
-28582000
+62.5%
-76278000
-53.8%
-49585000
EBITDA
-57638000
-13.7%
-50681000
-93.5%
-26191000
+63.1%
-71032000
-54.5%
-45965000
Net Income
-55427000
-28.4%
-43165000
-382.6%
-8945000
+84.3%
-57119000
-64.5%
-34727000
EPS (Basic)
$-0.18
-28.6%
$-0.14
-366.7%
$-0.03
+84.2%
$-0.19
-58.3%
$-0.12
EPS (Diluted)
$-0.18
-28.6%
$-0.14
-366.7%
$-0.03
+84.2%
$-0.19
-58.3%
$-0.12
Shares (Diluted)
305.6M
+0.8%
303.1M
+1.1%
299.8M
+0.3%
298.9M
+0.1%
298.5M
AbCellera Biologics Inc. Common Shares (ABCL) โ€” Financials